Morgan E. Meissner, Author at Rheumatology Advisor

Patient-Reported Outcomes (PROs) are symptoms patients with rheumatoid arthritis (RA) observe during the natural history of their disease. They provide clinicians with the patient’s perspective on her wellbeing. There is consensus on the importance of patient-reported pain, physical function, and global assessment of disease activity in assessing patients for treatment response.3 Many experts also consider fatigue and the duration of morning stiffness to be important PROs, but more data are needed to correlate these measures with outcomes. Other PROs with potential significance in assessing outcomes include flare, work participation or productivity, sleep quality, emotional distress, and coping.2,3 The use of PROs to assess disease activity allows patients with RA to take an active role in their treatment and contribute to RA research. Several challenges exist when incorporating PROs into practice, including variability in which PROs an instrument assesses and the heterogeneous nature of RA. Photo Credit: Dr P. Marazzi/Science Source

Gout

Serum CA72-4 Elevated in Gout, Predicts Future Flares in Patients With Gouty Arthritis

By

March 13, 2020

Researchers studied serum CA72-4 expression in patients with gout, and verified the hypothesis that CA72-4 was a predictor of future flares in gouty arthritis.

Pediatric Rheumatology

Identification of a Protein Epitope Targeted by the Kawasaki Disease Antibody Response

By

Morgan E. Meissner

March 12, 2020

A protein epitope targeted by the antibody response in children with Kawasaki disease has been identified.

Osteoporosis

Denosumab Decreases Vertebral Fracture Risk in Postmenopausal Women With Diabetes

By

Morgan E. Meissner

March 4, 2020

Denosumab increases bone mineral density and decreases vertebral fracture risk in postmenopausal women with osteoporosis and diabetes.

Osteoporosis

Evaluating Weekly Teriparatide vs Bisphosphonate Therapy After Lumbar Fusion in Patients With Osteoporosis

By

Morgan E. Meissner

February 28, 2020

Recovery after multilevel lumbar interbody fusion is similar between patients who receive weekly teriparatide and bisphosphonate therapy.

Osteoporosis

Vitamin D Supplementation Alone Does Not Increase Bone Structure, Strength

By

Morgan E. Meissner

February 4, 2020

In older adults, no significant changes in bone strength or structure were noted after 2 years of daily vitamin D supplementation.

Osteoporosis

Mineral, Hormonal Dysfunction Associated With Lower BMD in Thalassemia Major

By

Morgan E. Meissner

January 31, 2020

Hypothyroidism, hyperglycemia, and low adrenocorticotrophic hormone levels are associated with lower bone mass in patients with thalassemia major.

Osteoporosis

Later Puberty Associated With Lower Bone Mineral Density Accrual

By

Morgan E. Meissner

August 21, 2019

Older pubertal age was associated with lower BMD in adolescence and early adulthood, despite some catch-up during puberty.

Morgan E. Meissner

All articles by Morgan E. Meissner

Serum CA72-4 Elevated in Gout, Predicts Future Flares in Patients With Gouty Arthritis

Identification of a Protein Epitope Targeted by the Kawasaki Disease Antibody Response

Denosumab Decreases Vertebral Fracture Risk in Postmenopausal Women With Diabetes

Evaluating Weekly Teriparatide vs Bisphosphonate Therapy After Lumbar Fusion in Patients With Osteoporosis

Vitamin D Supplementation Alone Does Not Increase Bone Structure, Strength

Mineral, Hormonal Dysfunction Associated With Lower BMD in Thalassemia Major

Later Puberty Associated With Lower Bone Mineral Density Accrual

BMD in Osteoporosis Associated With Alterations in Abundance of Gut Microbiota